Skip to main content
Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
0.7459
-0.0317 (-4.08%)
Nov 12, 2026, 10:11 AM EST - Market open

Pliant Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---1.589.697.57
Revenue Growth
----83.69%27.91%-81.89%
Gross Profit
---1.589.697.57
Selling, General & Admin
32.3545.9259.0657.9339.9527.56
Research & Development
58.83104.16169.31127.896.9477.55
Operating Expenses
91.18150.07228.37185.73136.89105.11
Operating Income
-91.18-150.07-228.37-184.15-127.2-97.54
Interest Expense
-0.95-2.56-3.02-1.27-0.79-
Interest & Investment Income
7.9711.4221.0924.084.670.27
EBT Excluding Unusual Items
-84.16-141.22-210.3-161.34-123.32-97.26
Merger & Restructuring Charges
-6.3-6.3----
Other Unusual Items
-1.83-1.83----
Pretax Income
-92.29-149.34-210.3-161.34-123.32-97.26
Net Income
-92.29-149.34-210.3-161.34-123.32-97.26
Net Income to Common
-92.29-149.34-210.3-161.34-123.32-97.26
Net Income Growth
------
Shares Outstanding (Basic)
626161594236
Shares Outstanding (Diluted)
626161594236
Shares Change
0.97%1.37%3.10%39.75%17.21%67.94%
EPS (Basic)
-1.50-2.43-3.47-2.75-2.94-2.71
EPS (Diluted)
-1.50-2.43-3.47-2.75-2.94-2.71
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-70.9-128.71-159.35-117.28-96.39-77.4
Free Cash Flow Per Share
-1.15-2.10-2.63-2.00-2.29-2.16
Gross Margin
---100.00%100.00%100.00%
Operating Margin
----11654.75%-1313.37%-1288.10%
Profit Margin
----10211.14%-1273.32%-1284.51%
Free Cash Flow Margin
----7422.91%-995.26%-1022.13%
EBITDA
-89.87-148.38-226.24-182.3-125.38-96
D&A For EBITDA
1.311.72.131.841.821.54
EBIT
-91.18-150.07-228.37-184.15-127.2-97.54
SEC Filings: 10-K · 10-Q